Prostate-specific antigen (PSA) is used as a serum marker for PCa screening, or recurrence after therapy, although it cannot unequivocally discriminate between malignant and benign prostate disease requiring further diagnosis with imaging and/or biopsy [119]. This evidence concerns the gene KLK3 and posterior cortical atrophy.